Metabolic HealthThorne's Quercetin Phytosome Trial for Metabolic Health Was Terminated Early
Thorne HealthTech launched a clinical trial to test whether Quercetin Phytosome — a proprietary, higher-bioavailability form of the flavonoid quercetin — could improve metabolic health markers over 90 days. The study aimed to validate predictions from a computational model suggesting quercetin might benefit LDL cholesterol, blood sugar, liver and kidney function, immune markers, and a calculated 'metabolic age' score. Participants were asked to maintain consistent lifestyle habits to isolate the supplement's effects. Blood draws at baseline and day 90 would capture objective biomarker changes, while questionnaires tracked quality of life and compliance. The trial was ultimately terminated before completion, meaning no efficacy data was published. While quercetin's anti-inflammatory and antioxidant properties are well-established in preclinical research, this termination leaves a gap in human clinical evidence for its metabolic benefits.
